Free Trial
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Vertex Pharmaceuticals logo
$468.85 -10.68 (-2.23%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$467.85 -1.00 (-0.21%)
As of 07/11/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Key Stats

Today's Range
$467.97
$478.27
50-Day Range
$421.16
$500.19
52-Week Range
$377.85
$519.88
Volume
892,738 shs
Average Volume
1.42 million shs
Market Capitalization
$120.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$511.62
Consensus Rating
Moderate Buy

Company Overview

Vertex Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

VRTX MarketRank™: 

Vertex Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 128th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 13 buy ratings, 14 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Vertex Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Vertex Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Vertex Pharmaceuticals are expected to grow by 12.03% in the coming year, from $15.63 to $17.51 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vertex Pharmaceuticals is -119.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vertex Pharmaceuticals is -119.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vertex Pharmaceuticals has a P/B Ratio of 7.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vertex Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.50% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently decreased by 97.60%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vertex Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Vertex Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.50% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently decreased by 97.60%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Vertex Pharmaceuticals has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 42 news articles for Vertex Pharmaceuticals this week, compared to 30 articles on an average week.
  • Search Interest

    34 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 14 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,084.00 in company stock.

  • Percentage Held by Insiders

    Only 0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vertex Pharmaceuticals' insider trading history.
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

The Best Stocks to Invest $1,000 in Right Now
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Equities Analysts Offer Predictions for VRTX FY2025 Earnings
VRTX - Vertex Pharmaceuticals Inc News - Morningstar
See More Headlines

VRTX Stock Analysis - Frequently Asked Questions

Vertex Pharmaceuticals' stock was trading at $402.70 at the beginning of the year. Since then, VRTX stock has increased by 16.4% and is now trading at $468.85.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings results on Monday, May, 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by $0.23. The business's revenue was up 2.6% compared to the same quarter last year.
Read the conference call transcript
.

Vertex Pharmaceuticals subsidiaries include these companies: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others.

Top institutional investors of Vertex Pharmaceuticals include Swedbank AB (0.10%), Assenagon Asset Management S.A. (0.09%), Wealth Enhancement Advisory Services LLC (0.03%) and Gateway Investment Advisers LLC (0.03%). Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Charles F Wagner Jr, Bruce I Sachs, Bastiano Sanna, David Altshuler, Carmen Bozic, Edward Morrow Atkinson III, Jonathan Biller, Jeffrey M Leiden, Kristen Ambrose, Joy Liu, Sangeeta N Bhatia and Yuchun Lee.
View institutional ownership trends
.

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), QUALCOMM (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
5/05/2025
Today
7/12/2025
Next Earnings (Confirmed)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VRTX
CIK
875320
Employees
6,100
Year Founded
1989

Price Target and Rating

High Price Target
$586.00
Low Price Target
$420.00
Potential Upside/Downside
+9.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.54
Research Coverage
28 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
30.00
P/E Growth
N/A
Net Income
-$535.60 million
Net Margins
-8.91%
Pretax Margin
-2.70%
Return on Equity
-3.36%
Return on Assets
-2.42%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
2.65
Quick Ratio
2.29

Sales & Book Value

Annual Sales
$11.02 billion
Price / Sales
10.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$63.72 per share
Price / Book
7.36

Miscellaneous

Outstanding Shares
256,800,000
Free Float
256,283,000
Market Cap
$120.40 billion
Optionable
Optionable
Beta
0.41

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:VRTX) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners